Abstract:
PROBLEM TO BE SOLVED: To provide new compounds having immunomodulating activities and synthetic intermediates useful for production of these new compounds and particularly macrolide immunomodulators, and semisynthetic analogs of rapamycin and to provide a method for producing the semisynthetic analog and to provide a pharmaceutical composition containing the above compounds and to provide a therapeutic method using those. SOLUTION: The present invention provides new macrolide compounds, semisynthetic analogs of rapamycin and pharmaceutically acceptable salts, esters, amides and pro-drugs thereof and provides methods for producing the compounds and provides intermediates useful in these methods and a pharmaceutical composition, and provides a method of treating immunomodulatory disorders. COPYRIGHT: (C)2008,JPO&INPIT
Abstract:
PROBLEM TO BE SOLVED: To provide semisynthetic analogs of rapamycin as a therapeutic agent of immunomodulatory disorders. SOLUTION: Compounds such as semisynthetic analogs of rapamycin and pharmaceutically permissible salts, esters, amides, prodrugs and the like thereof are produced as a starting compound, which rapamycin is one of macrolide compounds obtained by fermentation and is a macrocyclic trien compound produced by Streptomyces hygroscopicus. Production of the intermediate useful for the methods, and use of the pharmaceutical compositions of the active ingredients and for treating immunomodulatory disorders, are provided. COPYRIGHT: (C)2008,JPO&INPIT
Abstract:
PROBLEM TO BE SOLVED: To provide a new semi-synthetic macrolide compound which has an immunomodulation activity and minimizes side effects. SOLUTION: This new semi-synthetic macrolide compound is obtained by converting a specific site of rapamycin into a specific substituent. The semi-synthetic macrolide has an immunomodulation action, and is effective for autoimmune diseases such as rejection, chronic articular rheumatism, systemic lupus erythematosus, chronic lymphocytic thyroiditis (Hashimoto disease), multiple sclerosis, myasthenia gravis, type I diabetes, uveitis, allergic encephalomyelitis, and glomerulonephritis. COPYRIGHT: (C)2008,JPO&INPIT
Abstract:
PROBLEM TO BE SOLVED: To provide a new macrolide compound, and to provide an immunomodulation medicine composition compounded with the compound. SOLUTION: The compound represented by formula (II), and the immunomodulation medicine composition compounded with the compound. COPYRIGHT: (C)2008,JPO&INPIT
Abstract:
PROBLEM TO BE SOLVED: To provide a new macrolide compound, to provide a rapamycin semi-synthetic analogue, and to provide their pharmaceutically acceptable salts, esters, amides and prodrugs. SOLUTION: A method for producing the compound represented by formula (IV), an intermediate useful for the method, a medicine composition, and a method for treating immunomodulation diseases are provided. COPYRIGHT: (C)2008,JPO&INPIT
Abstract:
PROBLEM TO BE SOLVED: To provide a new immunomodulation disease medicine. SOLUTION: The macrolide compound represented by formula (III) is provided. COPYRIGHT: (C)2008,JPO&INPIT
Abstract:
Oligopeptide compounds or oligopeptide analogue compounds of the formula A-B-D-E-G-J-L-M-Q-T are ligands for the anaphylatoxin receptor and are useful in the treatment of inflammatory disease states. Also disclosed are anaphylatoxin receptor ligand compositions and a method for modulating anaphylatoxin activity.
Abstract:
Compounds having Formula (I) are useful for modulating the glucocorticoid receptor in a mammal. Also disclosed are pharmaceutical compositions comprising compounds of Formula (I) and methods of treating immune, autoimmune, inflammatory, adrenal imbalance, cognitive and behavioral diseases in a mammal.
Abstract:
Immunomodulatory macrocylic compounds having the formula (VII) and pharmaceutically acceptable salts, esters, amides and prodrugs thereof, wherein X is selected from one of the formulae (Ia), (Ib) and (Ic), as well as pharmaceutical compositions containing the same.